NEW YORK – Adaptive Biotechnologies thinks its T-Detect test, launched this week for T cell-based diagnosis of COVID-19 infection, could be as disruptive to the molecular diagnostics industry as the Tesla Roadster was to the auto industry.
NEW YORK – Adaptive Biotechnologies thinks its T-Detect test, launched this week for T cell-based diagnosis of COVID-19 infection, could be as disruptive to the molecular diagnostics industry as the Tesla Roadster was to the auto industry.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.